TY  - BOOK
AU  - Sherine Abdelmoneim Abotaha
AU  - Nahed Abdelwahab Mohamed , 
AU  - Nevine Fawzy Shafik , 
AU  - Roxan Ezzat Shafik , 
TI  - Expression of CYP3A5*3 & CYP1A1*2C polymorphism in adult patient with acute myeloid leukaemia & relation with clinical response / 
PY  - 2017///
CY  - Cairo : 
PB  - Sherine Abdelmoneim Abotaha , 
KW  - Acute myeloid leukaemia
KW  - CYP3A5*3 & CYP1A1*2C
KW  - Polymorphism in adult
N1  - Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Clinical Pathology; Issued also as CD
N2  - Background: Genetic variations are one of the important factors in the development of acute leukemia. Molecular studies have proved that genetic polymorphism of metabolic enzymes influence the risk of a variety of tumors including leukemia. Cytochrome P450 (CYP) enzyme catalyzes the phase I metabolism reaction which metabolize endogenous and exogenous DNA-reactive chemical compounds and xenobiotics which could induce genotoxicity and increase the risk for leukemia. Aim of the study: To detect the frequency of CYP3A5*3 and CYP1A1*2C polymorphisms in Egyptian acute myeloid leukemia (AML) patients and to determine the role of genotypes variants as a risk factor for developing leukemia. Patient and Method: Detection of CYP3A5*3 and CYP1A1*2C polymorphisms using PCR-RFLP method in 70 newly diagnosed AML cases and 30 age and sex comparable healthy controls. Results: we found that CYP3A5*3 polymorphism (3/3) and (1/3) genotypes were significantly elevated in AML group compared to control group (p=0.002). However, no statistical significant differences were found between patients and control group as regard CYP1A1*2C polymorphism. Conclusion: Results suggest that Egyptians carrying CYP3A5*3 polymorphism might have an increased risk of AML emphasizing the significance of effective phase I detoxification in carcinogenesis
UR  - http://172.23.153.220/th.pdf
ER  -